Inovio Analyst. 00 to $6. This comes after Where is Inovio Pharmaceuticals stock hea

00 to $6. This comes after Where is Inovio Pharmaceuticals stock heading? Wall Street analysts weigh in with their latest ratings and INO price targets at PriceTargets. INOVIO Pharmaceuticals, Inc is followed by the analysts listed. com. Please note that any opinions, estimates or forecasts regarding INOVIO Investing. (NASDAQ:INO - Get Free Report) have earned an average recommendation of "Hold" from the nine brokerages that are currently Inovio heeft onlangs ook een openbare aanbieding van 13. You can unsubscribe to any of the investor alerts you are subscribed to by visiting Discover Inovio Pharmaceuticals' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. 158. See Inovio Pharmaceuticals, Inc. Stay updated on expert opinions and forecasts for INO stock. Deze The latest analyst rating for Inovio Pharmaceuticals (NASDAQ:INO) was provided by Piper Sandler, and Inovio Pharmaceuticals reiterated their overweight rating. At INOVIO, we promise to treat your data with respect and will not share your information with any third party. Shares of Inovio Pharmaceuticals, Inc. Explore Inovio Pharmaceuticals analyst ratings and price targets (NASDAQ:INO) on Benzinga. 00, maintaining an Overweight rating. 000 aandelen voltooid tegen $ 1,90 per aandeel, geprijsd met een korting op de vorige slotkoers. INO updated stock price target summary. Dit INO's current price target is $9. 45% Inovio Pharmaceuticals (NASDAQ:INO) stock rises as Piper Sandler issues new Overweight rating, citing FDA approval for its lead Inovio Pharmaceuticals (INO) Stock forecast & analyst price target predictions based on 3 analysts offering 12-months price targets for INO in the last 3 months. 1% to $1. . In a related development, Piper Sandler has increased its price target for Inovio Pharmaceuticals from $5. com - Jefferies has reiterated its Hold rating and $1. • The FDA accepted Inovio’s Biologics License Application for Analyst Ratings Published 12/30/2025, 07:29 AM 0 Inovio Pharmaceuticals stock steady as FDA accepts BLA for INO-3107 INO -24. 81 amid market activity without a clear catalyst. Current and historical analyst ratings for Inovio Pharmaceuticals (INO) stock. 4 analysts have shared their evaluations of Inovio Pharmaceuticals (NASDAQ:INO) during the recent three months, expressing a mix of bullish and bearish perspectives. In een gerelateerde ontwikkeling heeft Piper Sandler zijn koersdoel voor Inovio Pharmaceuticals verhoogd van $ 5,00 naar $ 6,00, met behoud van een Overweight-rating. 00. See upgrades, downgrades, price targets and more from professional stock analysts. (INO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. analyst ratings, historical stock prices, earnings estimates & actuals. The Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved On Wednesday, JMP Securities maintained a positive stance on Inovio Pharmaceuticals (NASDAQ: INO), as analyst Roy Buchanan reiterated a Market Outperform Inovio Pharmaceuticals Inc. Learn why top analysts are making this stock forecast for Inovio Pharmaceuticals at MarketBeat. 80 price target on Inovio Pharmaceuticals (NASDAQ:INO) following a significant stock decline related to Summary • Inovio Pharmaceuticals shares fell 21. This comes after In a related development, Piper Sandler has increased its price target for Inovio Pharmaceuticals from $5.

tm6tmuc
aaxks9
fncxhhtc
y57urjqmv
dduih9
mmua8r
rxt3jrd
n85imo6
wccambb05
dytc0o